Valneva SE (VALN) Total Liabilities (2020 - 2026)
Valneva SE (VALN) posted Total Liabilities of $345.7 million for Q1 2026, up 1.49% sequentially from $340.7 million in Q4 2025, and up 7.07% YoY from $322.9 million in Q1 2025.
Valneva SE (VALN) Total Liabilities (2020 - 2026) Analysis & Trends
Valneva SE has reported Total Liabilities for 7 years, with the latest figure at $345.7 million in Q1 2026.
- Quarterly Total Liabilities rose 7.07% year-over-year to $345.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $345.7 million (up 7.07% YoY) and the FY2025 annual result came in at $340.7 million, down 1.26% from the prior year.
- Total Liabilities rose to $345.7 million in Q1 2026 per VALN's latest filing, from $340.7 million in the prior quarter.
- Over five years, Total Liabilities peaked at $706.3 million in Q1 2022 and troughed at $322.9 million in Q1 2025.
- A 5-year average of $405.4 million and a median of $348.1 million in 2025 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2026: Total Liabilities plunged 44.63% in 2022, then grew 7.07% in 2026.
- Over 5 years, Total Liabilities stood at $409.7 million in 2022, then retreated by 12.86% to $357.0 million in 2023, then dropped by 4.58% to $340.6 million in 2024, then gained by 0.01% to $340.7 million in 2025, then increased by 1.49% to $345.7 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $345.7 million, $340.7 million, and $348.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | 357.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 357.03 Mn |
| Mar 31, 2026 | 345.74 Mn |
| Dec 31, 2025 | 340.68 Mn |
| Sep 30, 2025 | 348.09 Mn |
| Jun 30, 2025 | 323.96 Mn |
| Mar 31, 2025 | 322.92 Mn |
| Dec 31, 2024 | 340.65 Mn |
| Sep 30, 2024 | 328.53 Mn |
| Jun 30, 2024 | 323.38 Mn |
| Mar 31, 2024 | 340.68 Mn |
| Dec 31, 2023 | 357.01 Mn |
| Sep 30, 2023 | 395.18 Mn |
| Jun 30, 2023 | 383.15 Mn |
| Mar 31, 2023 | 413.47 Mn |
| Dec 31, 2022 | 409.68 Mn |
| Sep 30, 2022 | 537.51 Mn |
| Jun 30, 2022 | 674.22 Mn |
| Mar 31, 2022 | 706.29 Mn |
| Dec 31, 2021 | 739.89 Mn |
| Dec 31, 2020 | 443.22 Mn |